BridgeBio Pharma
BBIO
251 hedge funds and large institutions have $4.43B invested in BridgeBio Pharma in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 107 increasing their positions, 73 reducing their positions, and 36 closing their positions.
256% more call options, than puts
Call options by funds: $306M | Put options by funds: $85.9M
47% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 73
25% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 36
3% more funds holding
Funds holding: 244 → 251 (+7)
0.39% more ownership
Funds ownership: 93.11% → 93.5% (+0.39%)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
18% less capital invested
Capital invested by funds: $5.42B → $4.43B (-$989M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$54.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.8M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$29.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$27.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$86.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$36.8M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$32M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$28.5M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$21.5M |
BBIO Hedge Fund Activity: Q2 2024 in Review
251 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2024, worth a combined $4.43B — down 18% from $5.42B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BBIO positions and 36 closed out — a net gain of 9 holders — while 107 added to existing stakes and 73 trimmed.
The largest buyer was BlackRock, adding an estimated $54.2M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $86.7M sold.
- 251 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2024, up from 244 in Q1 2024.
- Funds reported $4.43B of BridgeBio Pharma stock for Q2 2024, down 18% quarter-over-quarter.
- 45 funds opened new BridgeBio Pharma positions in Q2 2024 and 36 closed out, a net change of +9 holders.
- The largest BridgeBio Pharma buyer in Q2 2024 was BlackRock, an estimated $54.2M added.
- The largest BridgeBio Pharma seller in Q2 2024 was Lord, Abbett & Co, an estimated $86.7M sold.
Based on aggregated 13F filings for Q2 2024.